As of 2026-10-02, the Intrinsic Value of ANI Pharmaceuticals Inc (ANIP) is 115.51 USD. This ANIP valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 72.96 USD, the upside of ANI Pharmaceuticals Inc is 58.30%.
The range of the Intrinsic Value is 72.08 - 268.12 USD
Based on its market price of 72.96 USD and our intrinsic valuation, ANI Pharmaceuticals Inc (ANIP) is undervalued by 58.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 72.08 - 268.12 | 115.51 | 58.3% |
| DCF (Growth 10y) | 86.73 - 295.83 | 133.41 | 82.9% |
| DCF (EBITDA 5y) | 69.26 - 189.97 | 96.19 | 31.8% |
| DCF (EBITDA 10y) | 87.10 - 226.21 | 119.32 | 63.5% |
| Fair Value | 119.02 - 119.02 | 119.02 | 63.13% |
| P/E | 24.85 - 74.25 | 51.87 | -28.9% |
| EV/EBITDA | 68.94 - 253.28 | 105.46 | 44.5% |
| EPV | 72.74 - 107.78 | 90.26 | 23.7% |
| DDM - Stable | 48.50 - 183.73 | 116.11 | 59.1% |
| DDM - Multi | 61.85 - 184.31 | 92.88 | 27.3% |
| Market Cap (mil) | 1,659.84 |
| Beta | 0.52 |
| Outstanding shares (mil) | 22.75 |
| Enterprise Value (mil) | 1,910.12 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.60% |
| Cost of Debt | 6.45% |
| WACC | 6.95% |